Actively Recruiting
Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy
Led by Ain Shams University · Updated on 2025-05-30
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of dexmedetomidine as an addition to bupivacaine in scalp blocks compared to bupivacaine alone for managing pain after craniotomy surgery. This study focuses on adults aged 18 to 65 undergoing planned supratentorial craniotomies to better understand how adding dexmedetomidine might affect postoperative pain relief and physiological responses. Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist known for its potential to enhance pain control when combined with local anesthetics. Participants will be randomly assigned to one of two groups: one group will receive a scalp block with bupivacaine alone, and the other will receive a scalp block with dexmedetomidine added to bupivacaine. Both treatments are delivered in the operating room as part of the anesthesia technique before surgery. This double-blind study ensures that neither the participants nor the researchers know which treatment is given. During the study, participants will be monitored for 24 hours after surgery. Researchers will assess cumulative morphine use, heart rate, blood pressure, pain levels, time until first rescue pain medication is needed, and any complications during this period. This monitoring helps understand how the treatments affect pain management and safety after craniotomy. The total participation includes surgery and the 24-hour postoperative observation.
CONDITIONS
Brief Title
Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age from 18 to 65 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) physical status I or II.
- Undergoing supratentorial elective planned craniotomies.
You will not qualify if you...
- Patients refusal.
- History of known allergy to the used local anesthetic or dexmedetomidine.
- Bleeding disorders.
- Evidence of local infection at the site of injection.
- Emergency craniotomy.
- Psychotic disorder.
- Patients who will not be extubated in the operating room after surgery.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During surgery
Participants receive a scalp block with either bupivacaine alone or bupivacaine combined with dexmedetomidine during their craniotomy surgery.
1 visit (in-person) for surgery and block administration
Duration - 24 hours postoperatively
Participants are monitored for pain management effectiveness and safety during the 24 hours following surgery.
Monitoring during hospital stay post-surgery
Trial Site Locations
Total: 1 location
1
Ain Shams University
Cairo, Egypt, 11591
Actively Recruiting
Research Team
O
Omar A Khiralla, MBBCH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here